DelSite Biotechnologies, Inc. Nasal Powder Vaccine Platform Highlighted At Cambridge Healthtech Institute  
8/18/2008 11:20:51 AM

IRVING, Texas, Aug. 18, 2008 (GLOBE NEWSWIRE) -- DelSite, Inc. (OTCBB:DSII) today announced Dr. Yawei Ni, Chief Scientific Officer of its wholly-owned subsidiary, DelSite Biotechnologies, Inc., presented data and development status of DelSite's GelVac(tm) nasal powder platform for vaccine delivery at the Cambridge Healthtech Institute's Third Annual Immunotherapeutics and Vaccine Summit held August 13-15, 2008, in Cambridge, Massachusetts.